lisdexamfetamine-dimesylate and Sleep-Wake-Disorders

Binge-eating disorder (BED) and night-eating syndrome (NES) are two forms of disordered eating associated with overweight and obesity. While these disorders also occur in nonobese persons, they seem to be associated with weight gain over time and higher risk of diabetes and other metabolic dysfunction. BED and NES are also associated with higher risk of psychopathology, including mood, anxiety, and sleep problems, than those of similar weight status without disordered eating. Treatments are available, including cognitive behavior therapy (CBT), interpersonal psychotherapy, lisdexamfetamine, and selective serotonin reuptake inhibitors (SSRIs) for BED; and CBT, SSRIs, progressive muscle relaxation, and bright light therapy for NES.

Topics: Antidepressive Agents; Anxiety Disorders; Binge-Eating Disorder; Clinical Trials as Topic; Comorbidity; Feeding Behavior; Female; Humans; Hydrocortisone; Lisdexamfetamine Dimesylate; Male; Metabolic Syndrome; Models, Psychological; Mood Disorders; Night Eating Syndrome; Obesity; Phototherapy; Prevalence; Psychotherapy; Relaxation Therapy; Selective Serotonin Reuptake Inhibitors; Serotonin; Sex Distribution; Sleep Wake Disorders; Stress, Psychological

Medication is an important element of therapeutic strategies for ADHD. While medications for ADHD are generally well-tolerated, there are common, although less severe, as well as rare but severe adverse events AEs during treatment with ADHD drugs. The aim of this review is to provide evidence- and expert-based guidance concerning the management of (AEs) with medications for ADHD.. For ease of use by practitioners and clinicians, the article is organized in a simple question and answer format regarding the prevalence and management of the most common AEs. Answers were based on empirical evidence from studies (preferably meta-analyses or systematic reviews) retrieved in PubMed, Ovid, EMBASE and Web of Knowledge through 30 June 2012. When no empirical evidence was available, expert consensus of the members of the European ADHD Guidelines Group is provided. The evidence-level of the management recommendations was based on the SIGN grading system.. The review covers monitoring and management strategies of loss of appetite and growth delay, cardiovascular risks, sleep disturbance, tics, substance misuse/abuse, seizures, suicidal thoughts/behaviours and psychotic symptoms.. Most AEs during treatment with drugs for ADHD are manageable and most of the times it is not necessary to stop medication, so that patients with ADHD may continue to benefit from the effectiveness of pharmacological treatment.

Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Blood Pressure; Body Size; Cardiovascular Diseases; Central Nervous System Stimulants; Child; Clonidine; Dextroamphetamine; Growth Disorders; Guanfacine; Heart Rate; Humans; Lisdexamfetamine Dimesylate; Methylphenidate; Propylamines; Psychoses, Substance-Induced; Seizures; Sleep Wake Disorders; Substance-Related Disorders; Suicide Prevention; Tic Disorders; Treatment Outcome